← All trials
NCT04523142
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 3, 2021
- Primary completion
- May 31, 2022
- Completion date
- Jun 30, 2022
- First posted
- Aug 21, 2020
- Last posted
- Sep 10, 2021
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Novaliq GmbHLead sponsor
- Novaliq GmbHStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.